Clene (CLNN) News Today $2.98 -0.02 (-0.67%) Closing price 05/2/2025 04:00 PM EasternExtended Trading$3.01 +0.03 (+1.14%) As of 05/2/2025 04:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period Clene Inc. (NASDAQ:CLNN) Receives $55.25 Average Price Target from AnalystsApril 26, 2025 | americanbankingnews.comClene initiated with a Buy at JonesResearchApril 24, 2025 | markets.businessinsider.comJones Trading Initiates Coverage of Clene (CLNN) with Buy RecommendationApril 23, 2025 | msn.comClene to Present at the Emerging Growth ConferenceApril 14, 2025 | globenewswire.comClene announces evidence of remyelination, neuronal repair with CNM-Au8April 8, 2025 | markets.businessinsider.comClene to Present at the Jones Healthcare and Technology Innovation ConferenceApril 1, 2025 | globenewswire.comClene files $160M mixed securities shelfMarch 26, 2025 | markets.businessinsider.comH.C. Wainwright Sticks to Their Buy Rating for Clene (CLNN)March 26, 2025 | markets.businessinsider.comClene to Participate in Jones Las Vegas Technology and Innovation Conference on April 8-9, 2025March 25, 2025 | finance.yahoo.comEQS-News: Clene to Participate in Jones Las Vegas Technology and Innovation Conference on April 8-9, 2025March 25, 2025 | markets.businessinsider.comClene Inc. Reports 2024 Financial Results and Strategic PlansMarch 25, 2025 | tipranks.comClene sees cash runway into 2Q25March 24, 2025 | markets.businessinsider.comClene Inc.: Clene Reports Full Year 2024 Financial Results and Recent Operating HighlightsMarch 24, 2025 | finanznachrichten.deClene Inc. Plans NDA Submission for CNM-Au8® in ALS and Initiates Phase 3 RESTORE-ALS Trial in 2025March 24, 2025 | quiverquant.comClene Reports Full Year 2024 Financial Results and Recent Operating HighlightsMarch 24, 2025 | globenewswire.comBullish Clene Insiders Loaded Up On US$583.4k Of StockMarch 20, 2025 | uk.finance.yahoo.comClene Inc.: Clene Demonstrates Strengthened ALS Survival Benefit with CNM-Au8 TreatmentMarch 12, 2025 | finanznachrichten.deClene announces evidence from post-hoc analysis of HEALY ALS platform trialMarch 12, 2025 | markets.businessinsider.comClene Demonstrates Strengthened ALS Survival Benefit with CNM-Au8® TreatmentMarch 12, 2025 | globenewswire.comClene (NASDAQ: CLNN) to Highlight Latest Achievements, Next Steps for CNM-Au8(R), at Q1 Virtual Investor SummitMarch 7, 2025 | theglobeandmail.comClene Inc. to Participate in 37th Annual Roth Conference with Virtual Fireside Chat and Investor MeetingsMarch 6, 2025 | quiverquant.comClene to Present at the 37TH Annual Roth ConferenceMarch 6, 2025 | globenewswire.comClene (NASDAQ: CLNN) Leverages APST’s NfL Database to Support FDA-Recommended Analyses for ALS DrugMarch 5, 2025 | theglobeandmail.comClene and APST Enter Into an Agreement to Support FDA’s Recommendation for Long-Term NfL Biomarker Analyses of CNM-Au8®’s Impact on NfL ReductionFebruary 25, 2025 | finance.yahoo.comClene, ASPT Research enter agreement to utilize NfL database for CNM-Au8February 25, 2025 | msn.comClene and APST Enter Into an Agreement to Support FDA's Recommendation for Long-Term NfL Biomarker Analyses of CNM-Au8®'s Impact on NfL ReductionFebruary 25, 2025 | globenewswire.comIs Clene Inc. (CLNN) the Best Nanotech Penny Stock to Invest In?February 14, 2025 | msn.comClene Inc. secures additional NIH grant funds for ALS therapyJanuary 30, 2025 | msn.comClene files to sell 1.15M shares of common stock for holdersJanuary 24, 2025 | markets.businessinsider.comIBN Coverage: Clene (NASDAQ: CLNN) Paves Cash Runway to Advance CNM-Au8(R) for ALSJanuary 13, 2025 | finance.yahoo.comIBN Coverage: Clene (NASDAQ: CLNN) Receives FDA Roadmap on Potential Accelerated Pathway for CNM-Au8(R)December 30, 2024 | finance.yahoo.comClene (NASDAQ: CLNN) Receives FDA Roadmap on Potential Accelerated Pathway for CNM-Au8(R)December 27, 2024 | theglobeandmail.comIBN Coverage: Clene (NASDAQ: CLNN) Secures $10M Debt Facility to Advance Neurodegenerative Disease TreatmentsDecember 21, 2024 | finance.yahoo.comClene Improves Cash Position and Runway by Securing New Debt Facility to Pay Off Existing Senior LoanDecember 19, 2024 | markets.businessinsider.comClene (NASDAQ: CLNN) Secures $10M Debt Facility to Advance Neurodegenerative Disease TreatmentsDecember 19, 2024 | theglobeandmail.comPromising Prospects for Clene’s ALS Treatment: Buy Recommendation Backed by Robust Data and Regulatory ProgressDecember 12, 2024 | markets.businessinsider.comIBN Coverage: Clene (NASDAQ: CLNN) Advances CNM-Au8 in ALS With FDA Guidance on Accelerated Approval PathwayDecember 12, 2024 | finance.yahoo.comClene Inc. Receives FDA Guidance on Accelerated Approval Pathway for CNM-Au8® in ALS, Plans NDA Submission for Mid-2025December 10, 2024 | quiverquant.comFDA Provides Roadmap for Accelerated Approval Pathway Through Submission of Additional CNM-Au8® Biomarker Data in ALSDecember 10, 2024 | globenewswire.comClene price target lowered to $84 from $90 at BenchmarkNovember 22, 2024 | markets.businessinsider.comClene price target lowered to $83 from $86 at CanaccordNovember 14, 2024 | markets.businessinsider.comClene’s Strategic and Financial Strengths Justify Buy Rating Amid Promising ALS Therapeutic DevelopmentsNovember 14, 2024 | markets.businessinsider.comClene Reports Third Quarter 2024 Financial Results and Recent Operating HighlightsNovember 13, 2024 | markets.businessinsider.comClene Reports Third Quarter 2024 Financial Results and Recent Operating HighlightsNovember 13, 2024 | markets.businessinsider.comClene Announces Q3 2024 Results and ALS Drug ProgressNovember 13, 2024 | markets.businessinsider.comClene Announces Q3 2024 Results and ALS Drug ProgressNovember 13, 2024 | markets.businessinsider.comIBN Coverage: Clene (NASDAQ: CLNN) Set to Discuss Lead Candidate Biomarker With FDA LeadershipOctober 25, 2024 | finance.yahoo.comClene (NASDAQ: CLNN) Set to Discuss Lead Candidate Biomarker with FDA LeadershipOctober 25, 2024 | theglobeandmail.comIBN Coverage: Clene (NASDAQ: CLNN) Presents Lead Candidate CNM-Au8(R) Updates at Investor ConferencesOctober 21, 2024 | finance.yahoo.comIBN Coverage: Clene (NASDAQ: CLNN) Closes $7.3M Registered Direct Offering and Concurrent Private PlacementsOctober 11, 2024 | finance.yahoo.com Get Clene News Delivered to You Automatically Sign up to receive the latest news and ratings for CLNN and its competitors with MarketBeat's FREE daily newsletter. Email Address CLNN Media Mentions By Week CLNN Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CLNN News Sentiment▼0.000.73▲Average Medical News Sentiment CLNN News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CLNN Articles This Week▼02▲CLNN Articles Average Week Get Clene News Delivered to You Automatically Sign up to receive the latest news and ratings for CLNN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies ENTX News Today MGNX News Today COYA News Today BHST News Today VXRT News Today ZNTL News Today SGMT News Today GNLX News Today ZURA News Today ATOS News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CLNN) was last updated on 5/4/2025 by MarketBeat.com Staff From Our PartnersElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredMost traders are panicking. We’re cashing inMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredTrump to solve American wealth loss?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | SponsoredElon Musk is all in on these robots …Robots — built by Nvidia. Forbes says this could be " a $24 trillion opportunity for investors." Huang s...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Clene Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Clene With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
